• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
30MayMay 30, 2025

Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study

28MayMay 28, 2025

The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy Adults

10DecDecember 10, 2024

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Abemaciclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b Results

10DecDecember 10, 2024

Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors and Everolimus

10DecDecember 10, 2024

Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Palbociclib in CDK4/6 Inhibitor–Resistant Wild-Type and Estrogen Receptor Y537S–Mutant Patient-Derived Xenograft Models

10NovNovember 10, 2024

Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants

31MayMay 31, 2024

TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer

15MayMay 15, 2024

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer: Updated Phase 1b Cohort Results

15MayMay 15, 2024

TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer

27MarMarch 27, 2024

The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader in Healthy Adult Participants

  Prev1234Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE